Sugi Predict

Sugi Predict / Compounds / SCHEMBL1923091

SCHEMBL1923091

SCHEMBL1923091

Cc1cc(C(=O)O)n(-c2c(C)nn3c(-c4ccc(Cl)cc4Cl)c(C)oc23)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 6/20 0.39
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MARS1 P56192 2/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ NTRK1 P04629 1/20 0.35
▸ CRHR1 P34998 4/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ DPP8 Q6V1X1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922972 0.89 KDM4E (0.38) DPP4NPC1KMT2ACNR1CNR2
SCHEMBL1922758 0.88 MAPT (0.42) DPP4LMNANPC1HSD17B10CNR1
SCHEMBL1922467 0.85 DPP4 (0.42) DPP4CYP2C9CYP2C19LMNANPC1
SCHEMBL1922662 0.83 DPP4 (0.41) DPP4CYP2C9CYP2C19NPC1CRHR1
SCHEMBL2256801 0.81 DPP4 (0.39) DPP4CYP2C9CYP2C19NPC1CRHR1
SCHEMBL1922297 0.81 LMNA (0.48) DPP4CYP2C9CYP2C19LMNANPC1
SCHEMBL1922397 0.79 CRHR1 (0.37) DPP4CYP2C9CYP2C19CRHR1CYP3A4
SCHEMBL1922525 0.78 DPP4 (0.44) DPP4CRHR1DPP8
SCHEMBL1922979 0.76 LMNA (0.40) DPP4LMNANPC1KMT2AMARS1
SCHEMBL1922037 0.76 DPP4 (0.45) DPP4LMNANPC1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011529943-A — — 2011-12-15 — — JP claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US claimed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP claimed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO claimed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 DPP4 958/4885CYP2C9 1426/4885CYP2C19 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.